3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Thyroid Cancer, Papillary
1
Sarcoma
1
Salivary Gland Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Nivolumab
21
cabozantinib
12
Specimen Handling
11
Ipilimumab
10
belzutifan
9
pembrolizumab
8
Magnetic Resonance Spectroscopy
8
CTLA-4 Antigen
5
Biopsy
5
Axitinib
5
lenvatinib
4
Sunitinib
4
Immunoglobulin G
3
Disulfides
3
zimberelimab
2
tivozanib
2
relatlimab
2
pazopanib
2
palbociclib
2
atezolizumab
2
aldesleukin
2
X-Rays
2
Watchful Waiting
2
Radiosurgery
2
Nephrectomy
2
Bevacizumab
2
ulixertinib
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
entrectinib
×
30 days
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA